Vir Biotechnology, Inc. has appointed Suzanne Topalian, M.D., to its Board of Directors. The appointment takes effect October 27, 2026. With this move, the company adds one of the field’s most respected cancer immunotherapy leaders to its boardroom.
Dr. Topalian currently serves as the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine. In addition, she works as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy. She also directs the Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins.
Vir Biotechnology’s leadership welcomed the news with enthusiasm. “Suzanne brings extraordinary depth of expertise in cancer immunotherapy and a track record of advancing groundbreaking science into meaningful solutions for patients,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. “Her perspective will be tremendously valuable as we continue to build our oncology portfolio and apply our integrated discovery and engineering capabilities with the broad potential of the PRO-XTEN® platform to develop new therapeutic approaches for patients with cancer.”
Suzanne Topalian’s Research Legacy in Cancer Immunotherapy
Dr. Topalian joins the board with an impressive scientific record. She is a physician-scientist and an internationally recognized leader in cancer immunotherapy. Her foundational research on anti-tumor immunity and PD-1 blockade helped establish immune checkpoint inhibition as a pillar of modern oncology.
Moreover, her published work carries significant weight across the scientific community. She has authored over 180 peer‑reviewed publications. As a result, she ranks among the most highly cited biomedical researchers.
Her achievements have earned numerous awards. Notably, the National Academy of Medicine elected her as a member in 2017. Furthermore, the American Association for Cancer Research (AACR) Academy honored her with election in 2022.
Dr. Topalian also shared her views on the company’s direction. “Vir Biotechnology is building a differentiated scientific foundation in oncology, bringing together impressive capabilities in the development of masked T-cell engagers that could unlock the potential of this powerful modality for solid tumors,” said Dr. Topalian. “I’m excited to join the Board and contribute to the accelerating momentum of the company’s clinical and strategic progress.”
Her academic path began with a B.A. in English from Wellesley College. Afterward, she earned her M.D. from Tufts University School of Medicine. She then completed postgraduate training in general surgery at Thomas Jefferson University Hospital. Finally, she trained in surgical oncology at the National Institutes of Health.
Overall, the Suzanne Topalian appointment strengthens Vir Biotechnology’s governance as the company expands its oncology portfolio. Her expertise in cancer immunotherapy should guide the board as Vir advances its work on masked T-cell engagers for solid tumors.
For more stories on technology leaders shaping the future of enterprise solutions, visit our CXO Insiders.
Source: Businesswire
